Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Polarean Imaging ( (GB:POLX) ) has issued an update.
Polarean Imaging plc has announced a strategic collaboration with SimonMed Imaging to integrate Polarean’s Xenon MRI platform into SimonMed’s expansive network of imaging facilities. This partnership aims to enhance diagnostic capabilities for pulmonary diseases by providing advanced imaging solutions that improve clinical outcomes. The first installation in Scottsdale, Arizona, signifies a significant business opportunity for both companies to expand the availability of functional lung imaging, aligning with their shared commitment to advancing patient care through innovative medical technologies.
More about Polarean Imaging
Polarean Imaging plc is a commercial-stage leader in advanced medical imaging, focusing on functional MRI of the lungs. The company is dedicated to revolutionizing pulmonary medicine by providing direct visualization of lung function. Polarean has developed the XENOVIEW® MRI technology platform, a non-invasive, radiation-free pulmonary functional MRI platform, that is aimed at addressing the global unmet medical needs of over 500 million patients with chronic respiratory diseases. The company is a pioneer in hyperpolarization science and its XENOVIEW® is FDA-approved in the United States.
YTD Price Performance: 40.0%
Average Trading Volume: 10,937
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $17.28M
For detailed information about POLX stock, go to TipRanks’ Stock Analysis page.
